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Introduction {#sec005}
============

Chronic kidney disease (CKD), characterized by progressive deterioration of biochemical and physiological functions of the body systems, can be defined as a syndrome caused by the progressive decrease in renal function \[[@pone.0229344.ref001]--[@pone.0229344.ref004]\].

In Brazil about 10 million people present some level of renal dysfunction, and the worldwide incidence of renal disease increases around 10% per year \[[@pone.0229344.ref005]\]. Because of the changes in life expectancy that have made the elderly become the dominant group in populations worldwide, the epidemiological figures of CKD are increasing continually, placing renal diseases in the epidemic category. This is a troubling situation and needs to be quickly controlled to try to minimize the devastating impacts of CKD, not only for patients, but also for public managers who have to invest large amounts of money in the attempt to provide quality treatment for those affected \[[@pone.0229344.ref006]\].

Recently, parallel to the classical causes of development and progression of CKD, Diabetes Mellitus (DM) and Systemic Arterial Hypertension (SAH), the use of drugs which were once considered safe have been identified as possible causes of renal damage. Among these drugs, proton pump inhibitors (PPI), highly prescribed worldwide to treat gastroesophageal reflux and peptic ulcers through inhibition of gastric acid synthesis, have shown to be closely associated with acute interstitial nephritis (AIN), reduction of glomerular filtration rate (GFR) and the development of CKD \[[@pone.0229344.ref007]--[@pone.0229344.ref011]\]

Initially it was believed that these drugs were associated with the development of recurrent acute renal injury, generating an AIN process that could be chronic and cause loss of renal function by successive renal tissue regeneration \[[@pone.0229344.ref007],[@pone.0229344.ref012],[@pone.0229344.ref013]\]. However, recent studies found that loss of renal function is not necessarily caused by sequential acute lesions, as the use of PPI has been associated with CKD regardless of the occurrence of previous acute episodes \[[@pone.0229344.ref008],[@pone.0229344.ref010]\].

The association between PPI use and CKD development is a recent and not fully understood topic. Only a few studies evaluating the impact generated by the use of these drugs, specifically on CKD progression and staging, have been performed. In addition, considering the high consumption of PPI in Brazil \[[@pone.0229344.ref014]\] and in the world population, as well their adverse effects, it is necessary to conduct researches to better elucidate this association. Such research may favor the creation of clinical protocols to promote the rational use of PPI, without disregarding the cost and benefit of this therapeutic approach. In this sense, the present study aims to analyze the association between the regular use of PPI and CKD progression in adult and elderly individuals, as well to analyze the survival of these patients.

Methods {#sec006}
=======

Ethical aspects {#sec007}
---------------

This study was approved by the Research Ethics Committee of the Federal University of São João del-Rei (UFSJ) Dona Lindu Center-West Campus CCO (CPEC: 65858117.3.0000.5545/nº 2.010.528).

Study design and population {#sec008}
---------------------------

This is a retrospective cohort study developed at the nephrology ambulatory sector of the Municipal Polyclinic of Divinópolis-MG, Brazil, from March 2017 to March 2019, following the STROBE checklist for observational research. Eligibility criteria were defined as all adult and elderly patients of both genders with established CKD diagnosis who were already undergoing clinical follow-up or who were diagnosed after insertion in the nephrology ambulatory clinic in the years 2016 and 2017. During this period, 241 patients were attended. Of these, 42 patients were excluded due to lack of confirmation of CKD diagnosis (28 cases), absent creatinine values (9 cases) and history of neoplasms (5 cases). Patients without baseline creatinine values (T0) were excluded from the study because it would not be possible to determine the estimated glomerular filtration rate (eGFR) and thus the baseline CKD stage. Similarly, those patients who had not recorded serum creatinine values at subsequent times (T1, T2, T3 and T4) were also excluded. Patients who underwent previous kidney transplantation and/or patients on renal replacement therapy, and patients who had missing data related to some of the variables used during the two-year follow-up were not included in this study. Thus, a total of 199 patients with CKD eligible for the study were included.

For all eligible patients, follow-up information was recorded for a period of two years after the date of insertion in the nephrology service. Baseline data was collected for population characterization at the initial moment (T0), and information about CKD staging of each patient included in the study was collected at five further times, at intervals of six months (T1, T2, T3 and T4).

Data collection {#sec009}
---------------

All variables were collected from two secondary sources: medical charts and the Brazilian health information system (SIS). The medical charts were evaluated for the presence of CKD diagnosis, for inclusion of patients in the study. After confirmation of the diagnosis, other variables were collected from this source: age in full years; gender; systolic and diastolic blood pressure (categorized as normal ≤ 120 / ≤ 80 mmHg and altered \> 120 / \> 80 mmHg) \[[@pone.0229344.ref015]\]; serum creatinine; eGFR; classification of CKD stage \[[@pone.0229344.ref004]\]; presence and/or absence of comorbidities; and prescribed medicines.

After collection of data from medical charts, data were collected from the SIS at baseline for complementation and confirmation of sociodemographic, occupational and clinical information and health-related behaviors: schooling; marital status; race; occupation; diagnosis of dyslipidemia; smoking; alcohol consumption; sedentary lifestyle; and dispensed medicines.

Exposure variable: Omeprazole use {#sec010}
---------------------------------

Among the PPI drugs available, only omeprazole was used by the patients evaluated in this study (daily dose of 20 mg). This can be justified because it is the only PPI available in the public pharmacies of Divinópolis-MG.

Regular users of omeprazole were considered those patients who had this medicine registered in the medical records for a period of three months or more during the data collection period. Such classification of the participants as current PPI users when the time of use was three months or more was based on the consultation of previous studies \[[@pone.0229344.ref008],[@pone.0229344.ref016]\]. Initially, users of omeprazole were considered as those who at baseline (T0) had used this drug previously for at least three months. Thereafter all patients defined as users were evaluated for the other times (T1, T2, T3, T4) for the use of omeprazole, and only those who maintained its use during all evaluation times for at least two years were included. Follow-up data on drug use were available for all follow-up times. Only patients who continued to use the drug during all assessment times were considered exposed to omeprazole. In the two years of follow-up, there was no change in the prescription for any of the patients included, maintaining the daily dose of 20 mg/ day. Those who discontinued omeprazole during follow-up were not included in the study.

Outcome variable: CKD stage evolution {#sec011}
-------------------------------------

In this study only patients with confirmed diagnosis of CKD were included, patients with acute kidney injury (AKI) and other renal diseases were not evaluated.

The evaluation of CKD stage and the identification of omeprazole users and non-users occurred at the time of diagnosis in the ambulatory clinic, followed by subsequent consultations. For a large number of patients, the CKD stage was available and recorded by the prescriber in the medical record at the time of the consultation. When the CKD stage was not available, the eGFR was calculated and classified according to the KDIGO \[[@pone.0229344.ref004]\] and MS \[[@pone.0229344.ref017]\] guidelines using the CKD-EPI equation without correction for race \[[@pone.0229344.ref018],[@pone.0229344.ref019]\]. Evolution of CKD was considered when the stage changed to a more advanced stage of renal impairment between one consultation to another, considering an increasing scale of severity starting from stage 1. In addition to this analysis, for each time, a 25% or more reduction in eGFR compared to the eGFR of the previous time was evaluated. Plus, a rapid progression analysis (5 mL/1.73m^2^/year) was performed as recommended by KDIGO \[[@pone.0229344.ref004]\].

Explanatory variables: Use of nephrotoxic and nephroprotective drugs {#sec012}
--------------------------------------------------------------------

In addition to PPI, the use of other drugs classically defined as nephrotoxic and nephroprotective agents was analyzed. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), included in current pharmacological nephroprotective therapy for patients with diabetic nephropathy and CKD, are recommended as nephroprotective agents according to the KDIGO \[[@pone.0229344.ref004]\] and MS \[[@pone.0229344.ref017]\] guidelines for the treatment of CKD patients. As for nephrotoxic drugs, non-steroidal anti-inflammatory drugs (NSAIDs) have been classically described as drugs with confirmed nephrotoxicity \[[@pone.0229344.ref020]\].

Despite the proposed collection regarding the use of other nephrotoxic drugs (aminoglycosides, lithium, amphotericin, acyclovir, foscarnet, polymyxins, glycopeptides, tacrolimus, cyclosporine, clopidogrel and interferon), only NSAIDs were prescribed/dispensed to the study population during the collection period. Thus, patients using these drugs were also evaluated, even patients using low-dose aspirin to prevent cardiovascular events.

The use of non-prescribed or drugs not reported at medical consultations was also evaluated using medicine dispensing reports in public pharmacies, generated by the Brazilian health information system (SIS), during the follow-up period.

Database design and processing {#sec013}
------------------------------

After all data were collected, a database was constructed and filled using Epidata software version 3.1. Data were double typed. The Kappa agreement test was applied to validate the database, resulting in a Kappa coefficient of 0.92, reflecting an almost perfect agreement (0.81--1.00) \[[@pone.0229344.ref021]\]. Data were exported to the Statistical Package for the Social Sciences (SPSS) version 20 for statistical analysis. The STATA SE version 12.0 software was used for Cox regression analysis.

Statistical analysis {#sec014}
--------------------

The study population was characterized through descriptive analysis. The Shapiro-Wilk test was applied to check the normality of the quantitative variables. The median and 25th and 75th percentiles were calculated, since all variables presented non-normal distribution. Relative frequency data were presented for the categorical variables. The Mann-Whitney U test and the Pearson/Fisher two-tailed chi-square test were used in the bivariate analysis.

Because this is a cohort study with a two-year follow-up and the defined outcome was the evolution of CKD to worse stages, Cox regression was used for the multivariate model to investigate the influence of time on the strength of association between omeprazole use and CKD evolution \[[@pone.0229344.ref022]\]. In order to determine the variables to be used in the multivariate analysis, univariate analysis using Cox regression was initially made, and variables that presented p-value \< 0.20 were considered eligible for the multivariate model. Thus, the following variables were used in the fitting of the multivariate analysis: omeprazole use and ARBs use.

After the multivariate analysis, Kaplan-Meier estimates were used to evaluate the evolution of risk to omeprazole users and non-users as a function of time.

Results {#sec015}
=======

The population of CKD diagnosed patients followed up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, during the years 2016 and 2017 was 204 people (37 excluded cases without CKD diagnosis). During this period, 406 patients attended consultations, resulting in a CKD prevalence of 50.24% in the nephrology ambulatory. The total of patients eligible for the study was 199, classified as omeprazole users (85) and non-users (114).

Of the patients evaluated, 64.5% lived with their partners, 51.7% were of the black/brown race, and 37.2% were retired. The most prevalent comorbidities were SAH (89.4%) and DM type II (39.7%).

The main sociodemographic and clinical characteristics and health behaviors of patients are described in [Table 1](#pone.0229344.t001){ref-type="table"}. A higher frequency of patients with altered blood pressure was found in the omeprazole group, and this difference was statistically significant (p-value = 0.016). No statistically significant difference was found between groups for the other variables, showing similarity between the groups studied.

10.1371/journal.pone.0229344.t001

###### Sociodemographic and clinical data and health behaviors of omeprazole users and non-users followed up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016--2017 (n = 199).

![](pone.0229344.t001){#pone.0229344.t001g}

  Variables                       General (n = 199)   Non-omeprazole users (n = 114)                              Omeprazole users (n = 85)                                   p-value
  ------------------------------- ------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------
  **Gender**                                                                                                                                                                  0.409[\*](#t001fn002){ref-type="table-fn"}
  Male                            54.3%               51.8%                                                       57.6%                                                       
  **Age**                         72 (62.0--80.0)     74 (62.5--80.0) [^\#^](#t001fn001){ref-type="table-fn"}     70 (61.0--79.5) [^\#^](#t001fn001){ref-type="table-fn"}     0.297[\*\*](#t001fn002){ref-type="table-fn"}
  **Schooling**                                                                                                                                                               0.884[\*](#t001fn002){ref-type="table-fn"}
  Illiterate                      12.3%               12.9%                                                       11.3%                                                       
  Incomplete elementary school    64.5%               63.4%                                                       66.1%                                                       
  Complete elementary school      11.6%               12.9%                                                       9.7%                                                        
  Others                          11.6%               10.8%                                                       12.9%                                                       
  **Blood pressure (S/D mmHg)**                                                                                                                                               0.016[\*](#t001fn002){ref-type="table-fn"}
  Normal (≤120/≤80)               72.4%               78.9%                                                       63.5%                                                       
  Altered (\>120/\>80)            27.6%               21.1%                                                       36.5%                                                       
  **Serum creatinine**            1.60 (1.40--2.00)   1.60 (1.40--2.05) [^\#^](#t001fn001){ref-type="table-fn"}   1.59 (1.40--1.99) [^\#^](#t001fn001){ref-type="table-fn"}   0.766[\*\*](#t001fn003){ref-type="table-fn"}
  **eGFR**                        37.0 (26.4--47.0)   35.8 (26.0--45.0) [^\#^](#t001fn001){ref-type="table-fn"}   38.9 (28.0--47.7) [^\#^](#t001fn001){ref-type="table-fn"}   0.215[\*\*](#t001fn003){ref-type="table-fn"}
  **Dyslipidemia**                                                                                                                                                            0.329[\*](#t001fn002){ref-type="table-fn"}
  Absent                          81.9%               84.2%                                                       78.8%                                                       
  Present                         18.1%               15.8%                                                       21.2%                                                       
  **Alcohol consumption**                                                                                                                                                     0.579[\*](#t001fn002){ref-type="table-fn"}
  No                              82.6%               80.0%                                                       85.2%                                                       
  Yes                             6.0%                8.3%                                                        3.7%                                                        
  Ex-consumer                     11.4%               11.7%                                                       11.1%                                                       
  **Smoking**                                                                                                                                                                 0.883[\*](#t001fn002){ref-type="table-fn"}
  No                              76.3%               77.6%                                                       74.5%                                                       
  Yes                             17.5%               17.2%                                                       18.2%                                                       
  Ex-Smoker                       6.2%                5.2%                                                        7.3%                                                        
  **Sedentary lifestyle**                                                                                                                                                     0.225[\*](#t001fn002){ref-type="table-fn"}
  No                              66.8%               71.9%                                                       60.0%                                                       
  Yes                             33.2%               28.1%                                                       40.0%                                                       
  **CKD stage**                                                                                                                                                               0.328[\*](#t001fn002){ref-type="table-fn"}
  Stage 2                         11 (5.5%)           7 (6.1%)                                                    4 (4.7%)                                                    
  Stage 3a                        62 (31.1%)          31 (27.2%)                                                  31 (36.5%)                                                  
  Stage 3b                        71 (35.7%)          42 (36.8%)                                                  29 (34.1%)                                                  
  Stage 4                         53 (26.6%)          32 (28.1%)                                                  21 (24.7%)                                                  
  Stage 5 ND                      2 (1.1%)            2 (1.8%)                                                    0 (0.0%)                                                    

\#Median (25th Percentile-- 75th Percentile).

\*Two-tailed Pearson chi-square test.

\*\*Non-parametric Mann-Whitney U test. S: Systolic; D: Diastolic; eGFR: Estimated glomerular filtration rate; ND: Non-dialytic.

The evaluated patients presented a median of 6.0 (4.0--8.0) for total medication use. Regarding the use of nephrotoxic and nephroprotective drugs, a frequency of 3.5% was found for NSAIDs, 21.6% for ACE inhibitors, and 61.3% for ARBs. No significant statistical difference was found between groups for these variables.

There was a significant difference in CKD evolution between omeprazole users and non-users (p \< 0.0001) ([Table 2](#pone.0229344.t002){ref-type="table"}). Confirming a higher CKD evolution in omeprazole users, a decrease in eGFR ≥ 25% was found in omeprazole users more frequently than in non-users, and this difference was statistically significant (p = 0.002). Regarding the rapid progression of CKD (5 mL/1.73m2/year), no statistically significant differences were found between users and non-users of omeprazole (p = 0.233).

10.1371/journal.pone.0229344.t002

###### Relative frequency of CKD evolution per stage of users and non-users of omeprazole followed-up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016--2017 (n = 199).

![](pone.0229344.t002){#pone.0229344.t002g}

  CKD evolution                General (n = 199)   Non-omeprazole users (n = 114)   Omeprazole users (n = 85)   p-value
  ---------------------------- ------------------- -------------------------------- --------------------------- ------------------------------------------------
  **Total**                    36.2%               10.5%                            70.6%                       \< 0.0001[\*](#t002fn001){ref-type="table-fn"}
  **Stage 2 → Stage 3a**       2.4%                0.0%                             5.5%                        
  **Stage 3a → Stage 3b**      16.9%               7.6%                             29.5%                       
  **Stage 3b → Stage 4**       12.9%               2.9%                             26.4%                       
  **Stage 4 → Stage 5 ND**     3.9%                0.0%                             9.2%                        
  **Stage 5 ND → Stage 5 D**   0.0%                0.0%                             0.0%                        

\* Two-tailed Pearson chi-square test; CKD: Chronic kidney disease; ND: Non-dialytic.; D: Dialytic.

The covariable ARBs use presented a p-value \< 0.20 and was then used to adjust the multivariate analysis through Cox regression. The use of the other drugs evaluated (NSAIDs, ACE inhibitors, ARBs) and blood pressure presented p-value\> 0.20 in the univariate Cox analysis, showing that these are not confounding variables and, therefore, not included as adjustment variables in the multivariate analysis. Initially, an unadjusted hazard ratio (HR) of 6.72 was obtained. After adjustment, a HR of 7.34 (CI 3.94--13.71) was found, indicating a risk of CKD progression approximately 7.4-fold higher in omeprazole users when compared to non-users. All adjustments made were statistically significant (p-value \< 0.05) ([Table 3](#pone.0229344.t003){ref-type="table"}).

10.1371/journal.pone.0229344.t003

###### Multivariate analysis using Cox regression for association between evolution of chronic kidney disease and omeprazole and ARBs use in patients followed-up at the nephrology ambulatory clinic of the Municipal Polyclinic of Divinópolis-MG, Brazil, 2016--2017 (n = 199).

![](pone.0229344.t003){#pone.0229344.t003g}

  Variables                        Hazard Ratio (HR)   Confidence Interval (95% CI)   p-value
  -------------------------------- ------------------- ------------------------------ -----------------------------------------------
  **Omeprazole use**                                                                  
  Non-users (reference category)   1.00                \-                             \-
  Users                            7.34                3.94--13.71                    \< 0.001[\*](#t003fn001){ref-type="table-fn"}
  **ARBs use**                                                                        
  Non-users (reference category)   1.00                \-                             \-
  Users                            0.60                0.37--0.96                     0.033[\*](#t003fn001){ref-type="table-fn"}

\* p-value \< 0.05

[Fig 1](#pone.0229344.g001){ref-type="fig"} shows the Kaplan-Meier survival plot for the worsening of CKD stage in omeprazole users and non-users. There was a higher risk of progression to worse stages among omeprazole users. At six months of follow-up, the risk of progression among omeprazole users was approximately 36.0%, while among non-users this risk was approximately 5.0%. It was observed that after the two-year follow-up, the risk of progression to a worse stage of CKD was approximately 84.0% among omeprazole users, while it was approximately 18.0% among non-users.

![Kaplan-Meier estimates for CKD progression among omeprazole users and non-users.\
Fig 1 shows the Kaplan-Meier survival plot for the occurrence of CKD evolution to worse stages in omeprazole users and non-users. The follow-up time is shown in the X axis and the cumulative risk of CKD evolution in the Y axis.](pone.0229344.g001){#pone.0229344.g001}

Discussion {#sec016}
==========

A statistically significant association was found between regular use of omeprazole and CKD progression in patients assisted at the nephrology ambulatory clinic (p-value \< 0.001), with a higher frequency of CKD progression for omeprazole users compared to non-users. After adjustments made in the multivariate analysis, a HR of 7.34 was obtained, indicating an approximately seven-fold higher risk of progression to a worse stage among patients using PPI. There is a limitation in the current literature with respect to studies associating CKD evolution and PPI use. A considerable number of studies only reported that long-term exposure to these drugs favors the onset of acute and also CKD, but they did not evaluate the progression of CKD in patients \[[@pone.0229344.ref007],[@pone.0229344.ref008],[@pone.0229344.ref010],[@pone.0229344.ref023],[@pone.0229344.ref024]\].

Investigating the possible mechanisms associated with renal damage caused by the use of PPI, Kamal et al. (2018) identified that the use of these drugs may be associated with the installation of a chronic process arising from a recurrent acute process, as well as the installation of the chronic process independent of the installation of AKI. In this sense, the authors propose some mechanisms that may be involved: the deposition of the drug and its metabolites in renal tissue, which may culminate in renal interstitial fibrosis, leading to chronicity of the lesion and onset of CKD; reduced nitric oxide synthesis, caused by inhibition of the proton pump of cell lysosomes, and thus production of highly reactive superoxide anion, which causes renal endothelial dysfunction; and hypomagnesemia, as low magnesium levels are able to increase secretion of atherogenic and inflammatory substances, producing endothelial dysfunction of the renal tissue \[[@pone.0229344.ref025]\].

In contrast to that presented for PPI, no results have yet been found that associate the use of H2 antagonists with the installation and/or progression of CKD. Some previous studies have suggested a possible association between the use of these drugs and the setting up of acute processes \[[@pone.0229344.ref026],[@pone.0229344.ref027]\], but these results are still controversial, as current studies have not found an association between the use of these drugs and the installation of acute or chronic processes \[[@pone.0229344.ref008], [@pone.0229344.ref009], [@pone.0229344.ref028]\]. Possibly this difference found between the use of PPI and H2 antagonists may be related to their respective mechanisms of action, since they are of different drug classes and trigger different physiological effects.

Regarding the deposition of drugs and their metabolites in renal tissue, H2 antagonists have already been mentioned, and possibly by this mechanism could be associated with acute processes, however, it should be noted that at initially a large number of drugs could trigger an inflammatory response in renal tissue \[[@pone.0229344.ref027]\]. Regarding nitric oxide synthesis, there are no studies to date that found an association between the reduction of its synthesis and H2 antagonists, an expected result since these drugs do not act by inhibiting proton pumps, but by blocking histamine receptors. (H2). Regarding hypomagnesemia, a population study conducted by Markovits et al (2014) found that the use of H2 antagonists is associated with mild hypomagnesemia, only in use for long periods, and found no association of these drugs with moderate or severe hypomagnesemia. For PPI, a significant association was found with a higher association strength for mild, moderate and severe hypomagnesemia \[[@pone.0229344.ref029]\]. Thus, it can be concluded that probably the mechanisms leading to the onset and progression of CKD by the use of PPI are associated with the onset of hypomagnesemia, as already proposed by Kamal et al. (2018) \[[@pone.0229344.ref025]\]. In fact, a variety of studies have found a significant association between PPI use and hypomagnesemia \[[@pone.0229344.ref028]--[@pone.0229344.ref032]\].

Hypomagnesemia associated with the use of PPI may be partly explained by the renal loss of magnesium due to decreased resorption as well as decreased absorption, as PPI are capable of altering the pH of the gastrointestinal tract, thereby decreasing absorption mediated by TRPM6 and TRPM7 transporters \[[@pone.0229344.ref032]\].

These findings, supported by what has already been described in the literature, draw attention to the fact that PPI nephrotoxicity is a risk not only for the initial onset of renal tissue damage but for a progressive loss of renal function when CKD is already present before the use of these drugs. In this sense, the present study brings results not yet explained in the current literature. Considering the present findings, it is necessary to rethink the use of these drugs in any CKD stage, as this can be an independent factor for worsening of renal function. Most worrying is that currently there is no restriction in this aspect in the guidelines for treatment of CKD patients, for either MS \[[@pone.0229344.ref017]\] or KDIGO \[[@pone.0229344.ref004]\]. It is important that the guidelines for treatment of CKD patients be updated, alerting them about these new risk factors and about the need for rational and cautious use of PPI.

In addition to the guidelines, immediate awareness about the harm caused by regular and continuous use of PPI is needed not only on the part of health professionals but also of CKD patients. This is necessary in particular because of the easy acquisition, at low cost, and the high frequency of inappropriate use of this drug, as already pointed out in the literature, with reports of use without clinical indication in 40--80% of cases \[[@pone.0229344.ref033],[@pone.0229344.ref034]\].

Regarding the sociodemographic characteristics, the patients in the present study were mostly male (54.3%) and of the white race (46.3%). According to Cobo et al., as happens in other diseases, the gender of the patient is of fundamental importance for the approach to CKD patients, because men and women differ in renal physiology and in the basic pathophysiology, complications, signs and symptoms of this disease, thus requiring a differentiated approach according to gender \[[@pone.0229344.ref035]\]. In general, females present greater renovascular resistance, lower absolute GFR, and lower renal flow than males \[[@pone.0229344.ref036]\], not to mention differences in the functional physiology of the renin angiotensin system and blood pressure control \[[@pone.0229344.ref037],[@pone.0229344.ref038]\]. Thus, it is necessary to emphasize the approach to female patients, in spite of all the risks for cardiovascular diseases (CVD).

Gender should be taken into account as a potential factor for increased risk of CVD. A precautionary and comprehensive approach is necessary without losing sight of the whole context involving CKD evolution and the risk of death from CVD. In none of these studies were found associations of gender with PPI use, or with the CKD evolution. In contrast, when it comes to the physiological loss of renal function with the advance of age, the female gender has shown to offer greater protection, which is explained by gender hormones and nitric oxide regulation, and consequent less reduction of renal aging \[[@pone.0229344.ref039]\]. As for race, in the United States of America, it is observed that African Americans present higher rates of renal diseases when compared to the other races \[[@pone.0229344.ref040]\]. However, in Brazil, relating race to renal function may not be prudent because there is a great racial miscegenation inherent in the national historical-cultural factor. In the present study, a number of studies conducted on Brazilian populations showed that race adjustment is not necessary for eGFR calculation, for example, because this variable does not interfere with the final results \[[@pone.0229344.ref041]--[@pone.0229344.ref043]\].

Regarding age group, the population assisted at the nephrology ambulatory clinic was mainly composed of elderly people (81.8%). This is worrisome because it implies two simultaneous risk factors: advanced age and PPI use without any level of restriction \[[@pone.0229344.ref044]\]. Perhaps this approach adopted by the ambulatory clinic so far has been based on the lack of regulations to guide a restrictive approach to PPI use.

In Beers criteria, which include actions related to the rational and safe use of drugs in elderly patients, there is no previous warning about the risk of renal damage due to PPI use in the elderly population \[[@pone.0229344.ref045]\]. This situation needs to be discussed because these drugs are frequently used in this age group and for long periods \[[@pone.0229344.ref046]\]. Furthermore, polypharmacy is usually common among elderly patients, which further corroborates the use of PPI to ensure protection of the gastric mucosa \[[@pone.0229344.ref047]\]. However, in the present study, no statistically significant difference was found in the age variable between groups of users and non-users of PPI (p \> 0.05).

Most patients assisted at the nephrology ambulatory clinic had incomplete primary education (64.5%), lived with their partners (64.7%), and were retired (37.2%). The low schooling found in this study for a population that is composed mainly of the elderly individuals is worrisome, because this population needs more health care and makes frequent use of a great quantity of medicines. Of course, the simple identification of the low level of education of these patients does not indicate that they are incapable of accessing health services, but it represents an increased likelihood of difficulty to understand guidelines provided in consultations, endorsed by the common loss of cognitive capacity typical of old age \[[@pone.0229344.ref036],[@pone.0229344.ref048]--[@pone.0229344.ref050]\].

The analysis of the clinical results showed a greater frequency of patients with altered arterial pressure in the omeprazole group, with a statistically significant difference between the groups (p-value 0.016). Montenegro et al. conducted a randomized clinical trial and identified that PPI are capable of interfering with the activation and bioavailability of oral nitrite, thus promoting an increase in nitrite-dependent systemic blood pressure, since its activation depends on the acidic environment promoted by gastric acid \[[@pone.0229344.ref051]\] which could perhaps explain the increased blood pressure in this group. In addition, some studies have reported that magnesium plays a key role in blood pressure control and hypomagnesaemia, which may occur in the use of PPI. Magnesium plays a key role in blood pressure control, as it is responsible for regulating intracellular protein contraction and mediating calcium influx, which is responsible for the contraction of smooth muscle cells by activating protein kinase C. In smooth muscle cells present in vascular endothelium, magnesium plays a role as a calcium antagonist, inhibiting its transmembrane transport and thereby reducing calcium-dependent vasoconstrictor capacity \[[@pone.0229344.ref052],[@pone.0229344.ref053]\]. Thus, hypomagnesemia may lead to increased calcium influx into vascular endothelial smooth muscle cells, causing vasoconstriction, further activation of cardiomyocytes, and a consequent increase in blood pressure \[[@pone.0229344.ref054],[@pone.0229344.ref055]\]. In this sense, in addition to favoring the increase in blood pressure, which in itself is a factor that worsens the prognosis of patients with kidney disease, the use of PPI may further increase the risk of CKD onset and progression, since hypomagnesemia leads to increased secretion of atherogenic and inflammatory substances, resulting in endothelial dysfunction of the renal tissue \[[@pone.0229344.ref025]\]. Thus, effective control of serum magnesium levels in patients with CKD, being PPI users, is a fundamental factor for a better prognosis of these patients.

However, this association cannot be confirmed in the present study because the magnesium values of the patients were not analyzed. These results show the need for monitoring magnesium levels in PPI users since the literature points out that the use of these drugs for long periods can be related to the development of hypomagnesaemia, thus generating other complications in users, such as SAH, for example \[[@pone.0229344.ref016],[@pone.0229344.ref025]\].

It is undeniable that PPI use can be a further risk factor for increasing blood pressure by decreasing oral nitrite bioavailability and reducing serum magnesium levels. However, especially in this group of patients, we should not lose sight of the fact that the determination of blood pressure in CKD patients is multifactorial because this is a complex physio-pathological context. To unequivocally establish this cause and effect relationship, more robust studies (such as randomized controlled trials) with control of all variables involved, are necessary. In addition, the population assisted at the nephrology ambulatory clinic had a median creatinine of 1.6 and an eGFR of 37.00, which reaffirmed a higher proportion of patients in stages 3a (31.1%) and 3b (35.7%) and the CKD stage may also be a direct factor determining blood pressure levels.

Concerning the comorbidities of the study population, DM II (39.7%) and SAH (89.4%) were the most prevalent. This result was already expected, since according to the last Brazilian Dialysis Census, these diseases remain as the main underlying causes of CKD \[[@pone.0229344.ref005]\]. Both are highly prevalent worldwide, with a high risk of mortality, and when uncontrolled, they are well-defined risk factors for the development of CKD and worsening of patient prognosis \[[@pone.0229344.ref004],[@pone.0229344.ref017]\].

Regarding health-related behaviors, no significant statistical difference was found between users and non-users of omeprazole in relation to the variables evaluated. The majority of the patients followed-up at the nephrology ambulatory clinic in this study presented healthy life habits, since 82.6% were not alcohol consumers, 76.3% were non-smokers, and 66.8% were non-sedentary. In addition, 81.9% of them did not have dyslipidemia. In 2018, Kamal et al. (2018) reported that prolonged use of PPI is an isolated risk factor for the development of CVD \[[@pone.0229344.ref025]\]. Thus, the life habits of the patients in the present study represented a favorable finding and perhaps a positive influence on their prognosis. Although exposed to omeprazole, there were modifiable risk factors that could potentiate the worsening of renal function and consequently increase of the risk of CVD. However, these risk factors were controlled.

Another finding that seemed to favor the renal prognosis of the patients studied was the very low frequency of use of NSAIDs (3.5%). These drugs are known to be nephrotoxic and potentiated in the elderly \[[@pone.0229344.ref045],[@pone.0229344.ref056],[@pone.0229344.ref057]\]. This low frequency is probably justified by their known nephrotoxicity. In clinical practice, many prescribers use them with caution or avoid their prescription for CKD patients. Regarding nephroprotective drugs, ARBs were the most used (61.3%) followed by ACE inhibitors (21.6%). At least 61.3% of the CKD patients treated at the nephrology ambulatory clinic used at least one drug as a nephroprotection mechanism, which is a favorable profile of use for these patients.

Due to the characteristics of the study population (mostly elderly and with CKD), polypharmacy was common, as expected, both among users and non-users of omeprazole, with a median of seven and six medications, respectively. However, it was not possible to evaluate in this study the real benefit or harm of polypharmacy, since this requires another set of analysis of associations between the use of each drug, considering all the confounding variables, with the outcome of CKD evolution.

Returning to the discussion of renal impairment caused by regular use of PPI, the idea of recovering histamine receptor antagonists, predecessors to PPI used for the treatment of gastric diseases, has been raised as a more protective option to renal functions \[[@pone.0229344.ref008],[@pone.0229344.ref009],[@pone.0229344.ref058]\]. In recent meta-analysis, Wijarnpreecha et al. (2017) found a 1.3-fold increased risk for CKD onset and evolution to ESRD for PPI users. For the H2 antagonist users this risk was not found \[[@pone.0229344.ref059]\]. Xie et al. (2016) found in a cohort study that PPI users have a higher risk of CKD onset and evolution, as well as to progression to ESRD, when compared to users of H2 antagonists and controls \[[@pone.0229344.ref060]\]. Thus, these drugs emerge as a plausible alternative for the prevention and treatment of gastric diseases without the high risk of impaired renal function.

Finally, it is important to emphasize that despite the inestimable value of the findings of this study for clinical practice, it is necessary to recognize some limitations. Although this was a cohort study, a retrospective cohort design with use of secondary data (medical records and the health information system) favors biases such as selection and information typical of retrospective cohorts \[[@pone.0229344.ref061]\]. However, the selection bias was minimized by using the entire ambulatory population of CKD patients, thus preventing further omeprazole users who evolved from being selected. Regarding information bias, it is extremely important to consider possible errors in registration data of both sources. To reduce their occurrence, two data sources were used, which when compared, allowed the confirmation and complementation of missing data. In addition, double entry was made in the database in order to reduce the chances of registration errors of the collected data. Furthermore, the analyses were made with drug classes and with the total number of drugs in use, but the drugs were not analyzed individually. The evaluated drugs are commonly used in self-medication, and this prevents the evaluation of possible interference in these cases based on the use of secondary data. In the case of some variables, a large amount of missing data was detected at the time of data collection. This made it impossible to use such variables in the analyses of this study. Prior to the removal of these variables, an analysis was performed to verify the possibility that they could be confounding factors, being confirmed as not influencing the final result. In this sense, a need to raise awareness among primary care professionals about the importance of properly completing the information required in health information systems was found. Despite these limitations, the quality of this study and the strength of the association found are not impaired. Furthermore, no statistically significant differences were found between the groups in most of the variables evaluated, reflecting high homogeneity between the groups evaluated, allowing a more reliable comparison between them.

The findings of this study are extremely important, since they contribute to the change of the approach in clinical practice. They also corroborate with results found in previous studies regarding the nephrotoxicity of PPI and their relation to CKD. The study alerts prescribers about the importance of rational use of PPI in patients without renal impairment, as well as the importance of avoiding them whenever possible in the therapy of CKD patients. Finally, the study contributes to the elaboration of updated guidelines for the adequate pharmacological treatment of elderly and/or CKD patients.

Conclusion {#sec017}
==========

There was a significant association between regular use of omeprazole and progression to worse stages of CKD in adult and elderly individuals followed-up at the nephrology ambulatory clinic at the Municipal Polyclinic of Divinópolis. Appropriate guidelines for health professionals about PPI nephrotoxicity need to be developed in order to preserve the renal function in elderly and/or CKD patients.
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The manuscript focuses on a topic of potential interest. However, the manuscript shows major shortcomings that should be addressed. To mention few of them, i) concern about the fact that it appears that there was a single evaluation as to whether or not the patients were on a PPI or not at the baseline visit; ii) need to perform analysis using PPI use as the time-varying variable; iii) need to specify the definition of PPI use in term of dose and duration; iv) concern about the use and definition of CKD stage evolution as outcome variable which is inadequate/incomplete; v) perform additional analysis on rapid progression; vi) clearly define the baseline creatinine; vii) need to further discuss and in more depth the association between PPI use and CKD; viii) unclear whether the investigators excluded kidney transplant patients; ix) need to follow the STROBE checklist; x) discuss the limitations of the findings of the study; xi) unclear whether the her blood pressure in the group with PPI than the group without PPI has been taken into account in the multivariate analysis.
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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Kind regards,

Giuseppe Remuzzi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: It is an interesting and relevant article. I consider it a useful contribution in its field of nephrology; in which I agree with the authors that no prior study has been capable of identifying an association between the use of PPI by CKD patients with and the progression of this disease.

However, there are major modifications and clarifications that are strongly needed for this study. Avoidance of modifications to improve manuscript/study is discouraged.

1\. It appears that there was a single evaluation as to whether or not the patients were on a PPI or not at the baseline visit. Is it assumed that all patients who were documented as being on a PPI at baseline were on PPIs permanently and that none of those in the non-PPI group were ever started on a PPI? PPI use can change over time. Can you perform analysis using PPI use as the time-varying variable? Lack of longitudinal data on PPI use - this appears to be based on documented PPI intake at a single time point. Thus, consider performing analysis using PPI use as the time-varying variable

2\. Please specify the definition of PPI use in term of dose and duration

3\. The use and definition of CKD stage evolution as Outcome variable is inadequate/incomplete. In addition to Decline in GFR category, the authors/investigators need to look into "A certain drop in eGFR is defined as a drop in GFR category accompanied by a 25% or greater drop in eGFR from baseline". Thus, 25% or greater drop in eGFR from baseline should be taken into consideration

4\. Additional analysis is needed on Rapid progression in which is defined as a sustained decline in eGFR of more than 5 mL/1.73m2/year, as KDIGO recommended.

5\. In order to perform 1) and 2) for validity, baseline creatinine definition will need to be clear defined. Most recent vs. minimum baseline creatinine? When baseline creatinine is not available, SCrGFR-75 is suggested, when baseline outpatient SCr was not available or may need to exclude those patients from the study. Need clearer describe in the method.

6\. Association between PPI use and CKD needs better discussed. In fact, recent meta-analysis showed 1.3-fold increased risks of CKD and ESRD in patients using PPIs, but not in patients using H2RAs. PMID: 28836158

7\. RE "some studies have reported that magnesium plays a key role in blood pressure control and hypomagnesaemia, which may occur in the use of PPI, a possible cause of arterial hypertension resulting from increased calcium influx in smooth muscle cells of the vascular endothelium"; need better discussion; this statement is unclear. The use of PPIs has been shown to be associated with 1.43-fold increased risk of hypomagnesemia compared to those who did not use PPIs. PMID: 26108134. The underlying mechanism of the association of hypomagnesemia in patients with PPI use is likely explained by the disturbance of gastrointestinal (GI) handling of Mg since studies have shown that an increased renal Mg loss is not the only culprit in those patients with significant hypomagnesemia after PPI use.

8\. Did the investigator exclude kidney transplant patients?

9\. The STROBE checklist is needed to be followed. There are a number of consistent inaccuracies in the manuscript that I strongly believe need to be addressed before the paper can be reviewed again.

10\. Please discuss in the limitations the types of biases the findings of this study may be influenced by.

11\. Some revision of the English language is needed. There are some parts of the paper where it is quite difficult to make sense of some sentences. English edit will help to improve the quality of the manuscript.

"they identified that PPI are associated" is not correct in grammar.

RE "medicine use were collected from all patients diagnosed with CKD"; "medicine use" should be "medication use"

RE "the progressive decrease of renal function" "of" should be "in"

"In addition, considering the high consumption of PPI in the world and 78 in the Brazilian population \[14\] and their adverse effects on renal functions, perform research to 79 contribute to the reduction of the knowledge gap with respect to this association, and of the very use of 80 these drugs, is paramount." Is not well written and difficult to follow.

Reviewer \#2: Dear author,

Thanks for interesting article that brings new evidence of the renal toxicity of the proton pump inhibitor.

I would like to clarify a few points:

\> major revision

The group with proton pump inhibitor has a higher blood pressure than the group without proton pump inhibitor. This difference alone can explain the progression of renal failure. it is not clear that this has been taken into account in the multivariate analysis.

\> minor revision

in the table on page 10, for which data with ACEs do not appear?

\> This is not the first time a study has focused on the progression of kidney failure. For example, XIE Y JASN 2016 has demonstrated a link between proton pump inhibitor and 30% decrease in GFR or doubling of creatinine level.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Desbuissons Geoffroy

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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October 27th, 2019.

Dear Editor Giuseppe Remuzzi,

Initially, we would like to thank you and the reviewers for their kind comments that helped us to improve our paper. We are resubmitting the revised manuscript for re-evaluation. We hope these revisions are satisfactory. If you require any further information please do not hesitate to contact us.

We inform that the manuscript has been modified according to the templates provided. Also, we would like to point out that the database was attached containing only the data necessary for the reproduction of the results obtained, in order to ensure the confidentiality of patients, as recommended by the Brazilian legislation on research ethics with human beings (RESOLUÇÃO Nº 510, DE 07 DE ABRIL DE 2016).

All statements made by the editor and the reviewers were considered in the revision of this manuscript, and answered as follows:

Reviewer \#1: It is an interesting and relevant article. I consider it a useful contribution in its field of nephrology; in which I agree with the authors that no prior study has been capable of identifying an association between the use of PPI by CKD patients with and the progression of this disease.

However, there are major modifications and clarifications that are strongly needed for this study. Avoidance of modifications to improve manuscript/study is discouraged.

1\. It appears that there was a single evaluation as to whether or not the patients were on a PPI or not at the baseline visit. Is it assumed that all patients who were documented as being on a PPI at baseline were on PPIs permanently and that none of those in the non-PPI group were ever started on a PPI? PPI use can change over time. Can you perform analysis using PPI use as the time-varying variable? Lack of longitudinal data on PPI use -- this appears to be based on documented PPI intake at a single time point. Thus, consider performing analysis using PPI use as the time-varying variable.

Answer: The following sentence has been included in the text for further clarification:

"Initially, users of omeprazole were considered as those who at baseline (T0) had used this drug previously for at least three months. Thereafter all patients defined as users were evaluated for the other times (T1, T2, T3, T4) for the use of omeprazole, and only those who maintained its use during all evaluation times for at least two years were included. Follow-up data on drug use were available for all follow-up times. Only patients who continued to use the drug during all assessment times were considered exposed to omeprazole. In the two years of follow-up, there was no change in the prescription for any of the patients included, maintaining the daily dose of 20 mg/ day. Those who discontinued omeprazole during follow-up were not included in the study."

2\. Please specify the definition of PPI use in term of dose and duration

Answer: As presented above information regarding the omeprazole use, dose and duration are described in the exposure variable section and were adequate for better understanding:

"Initially, users of omeprazole were considered as those who at baseline (T0) had used this drug previously for at least three months. Thereafter all patients defined as users were evaluated for the other times (T1, T2, T3, T4) for the use of omeprazole, and only those who maintained its use during all evaluation times for at least two years were included. Follow-up data on drug use were available for all follow-up times. Only patients who continued to use the drug during all assessment times were considered exposed to omeprazole. In the two years of follow-up, there was no change in the prescription for any of the patients included, maintaining the daily dose of 20 mg/ day. Those who discontinued omeprazole during follow-up were not included in the study."

3\. The use and definition of CKD stage evolution as Outcome variable is inadequate/incomplete. In addition to Decline in GFR category, the authors/investigators need to look into "A certain drop in eGFR is defined as a drop in GFR category accompanied by a 25% or greater drop in eGFR from baseline". Thus, 25% or greater drop in eGFR from baseline should be taken into consideration

Answer: As proposed by the reviewer, in addition to investigating the CKD evolution by changing to a worse stage of the disease, we also assessed a reduction in eGFR ≥ 25% for all follow-up times in users and non-users of omeprazole. Thus, the following excerpts were inserted in the manuscript:

"\[\...\] In addition to this analysis, for each time, a 25% or more reduction in eGFR compared to the eGFR of the previous time was evaluated." (Methods section)

\[\...\] "Confirming a higher CKD evolution in omeprazole users, a decrease in eGFR ≥ 25% was found in omeprazole users more frequently than in non-users, and this difference was statistically significant (p = 0.002)." (Results)

4\. Additional analysis is needed on Rapid progression in which is defined as a sustained decline in eGFR of more than 5 mL/1.73m2/year, as KDIGO recommended.

Answer: As suggested by the reviewer, CKD rapid progression analysis was performed, finding no statistically significant differences between users and non-users of omeprazole (p = 0.233). Thus, the following excerpts were inserted into the manuscript:

"Plus, a rapid progression analysis (5 mL/1.73m2/year) was performed as recommended by KDIGO \[4\]." (Methods: Outcome variable section)

"Regarding the rapid progression of CKD (5 mL/1.73m2/year), no statistically significant differences were found between users and non-users of omeprazole (p = 0.233)." (Results Section)

5\. In order to perform 1) and 2) for validity, baseline creatinine definition will need to be clear defined. Most recent vs. minimum baseline creatinine? When baseline creatinine is not available, SCrGFR-75 is suggested, when baseline outpatient SCr was not available or may need to exclude those patients from the study. Need clearer describe in the method.

Answer: As thought by the reviewer, patients who did not have creatinine values at baseline or sequential times studied were excluded from the study. This information is described in Methods: Study design and population. Serum creatinine basal values as well as serum creatinine values from subsequent times were described in the medical records and were used to calculate eGFR, and thus to classify the CKD stage for each time. In this regard, in order to clarify this information, the following sentence has been inserted in the text:

"Patients without baseline creatinine values (T0) were excluded from the study because it would not be possible to determine the estimated glomerular filtration rate (eGFR) and thus the baseline CKD stage. Similarly, those patients who had not recorded serum creatinine values at subsequent times (T1, T2, T3 and T4) were also excluded."

6\. Association between PPI use and CKD needs better discussed. In fact, recent meta-analysis showed 1.3-fold increased risks of CKD and ESRD in patients using PPIs, but not in patients using H2Ras. PMID: 28836158

Answer: To improve the discussion about the association between the use of PPI and CKD, there was a discussion about the possible mechanisms associated with renal injury, comparing the findings regarding the use of PPIs with H2 antagonists, clarifying aspects concerning this association. Results that explain these findings were explained using the reference cited, as well as others for complementation. The following excerpts have been inserted:

"Investigating the possible mechanisms associated with renal damage caused by the use of PPI, Kamal et al. (2018) identified that the use of these drugs may be associated with the installation of a chronic process arising from a recurrent acute process, as well as the installation of the chronic process independent of the installation of AKI. In this sense, the authors propose some mechanisms that may be involved: the deposition of the drug and its metabolites in renal tissue, which may culminate in renal interstitial fibrosis, leading to chronicity of the lesion and onset of CKD; reduced nitric oxide synthesis, caused by inhibition of the proton pump of cell lysosomes, and thus production of highly reactive superoxide anion, which causes renal endothelial dysfunction; and hypomagnesemia, as low magnesium levels are able to increase secretion of atherogenic and inflammatory substances, producing endothelial dysfunction of the renal tissue \[25\]."

"In contrast to that presented for PPI, no results have yet been found that associate the use of H2 antagonists with the installation and/or progression of CKD. Some previous studies have suggested a possible association between the use of these drugs and the setting up of acute processes \[26,27\], but these results are still controversial, as current studies have not found an association between the use of these drugs and the installation of acute or chronic processes \[8, 9, 28\]. Possibly this difference found between the use of PPI and H2 antagonists may be related to their respective mechanisms of action, since they are of different drug classes and trigger different physiological effects."

"Regarding the deposition of drugs and their metabolites in renal tissue, H2 antagonists have already been mentioned, and possibly by this mechanism could be associated with acute processes, however, it should be noted that at initially a large number of drugs could trigger an inflammatory response in renal tissue \[27\]. Regarding nitric oxide synthesis, there are no studies to date that found an association between the reduction of its synthesis and H2 antagonists, an expected result since these drugs do not act by inhibiting proton pumps, but by blocking histamine receptors. (H2). Regarding hypomagnesemia, a population study conducted by Markovits et al (2014) found that the use of H2 antagonists is associated with mild hypomagnesemia, only in use for long periods, and found no association of these drugs with moderate or severe hypomagnesemia. For PPI, a significant association was found with a higher association strength for mild, moderate and severe hypomagnesemia \[29\]. Thus, it can be concluded that probably the mechanisms leading to the onset and progression of CKD by the use of PPI are associated with the onset of hypomagnesemia, as already proposed by Kamal et al. (2018) \[25\]. In fact, a variety of studies have found a significant association between PPI use and hypomagnesemia \[28-32\]."

"Hypomagnesemia associated with the use of PPI may be partly explained by the renal loss of magnesium due to decreased resorption as well as decreased absorption, as PPI are capable of altering the pH of the gastrointestinal tract, thereby decreasing absorption mediated by TRPM6 and TRPM7 transporters \[32\]."

7\. RE "some studies have reported that magnesium plays a key role in blood pressure control and hypomagnesaemia, which may occur in the use of PPI, a possible cause of arterial hypertension resulting from increased calcium influx in smooth muscle cells of the vascular endothelium"; need better discussion; this statement is unclear. The use of PPIs has been shown to be associated with 1.43-fold increased risk of hypomagnesemia compared to those who did not use PPIs. PMID: 26108134. The underlying mechanism of the association of hypomagnesemia in patients with PPI use is likely explained by the disturbance of gastrointestinal (GI) handling of Mg since studies have shown that an increased renal Mg loss is not the only culprit in those patients with significant hypomagnesemia after PPI use."

Answer: In order to better elucidate a higher frequency of altered blood pressure found in PPIs users in the univariate analysis, we used studies to find a possible association between the use of these drugs, hypomagnesemia, blood pressure and CKD. For a better discussion of this, the following excerpt has been inserted into the manuscript:

"\[...\] Magnesium plays a key role in blood pressure control, as it is responsible for regulating intracellular protein contraction and mediating calcium influx, which is responsible for the contraction of smooth muscle cells by activating protein kinase C. In smooth muscle cells present in vascular endothelium, magnesium plays a role as a calcium antagonist, inhibiting its transmembrane transport and thereby reducing calcium-dependent vasoconstrictor capacity \[52,53\]. Thus, hypomagnesemia may lead to increased calcium influx into vascular endothelial smooth muscle cells, causing vasoconstriction, further activation of cardiomyocytes, and a consequent increase in blood pressure \[54,55\]. In this sense, in addition to favoring the increase in blood pressure, which in itself is a factor that worsens the prognosis of patients with kidney disease, the use of PPI may further increase the risk of CKD onset and progression, since hypomagnesemia leads to increased secretion of atherogenic and inflammatory substances, resulting in endothelial dysfunction of the renal tissue \[25\]. Thus, effective control of serum magnesium levels in patients with CKD, being PPI users, is a fundamental factor for a better prognosis of these patients."

"\[...\] In fact, a variety of studies have found a significant association between PPI use and hypomagnesemia \[28-32\]."

"Hypomagnesemia associated with the use of PPI may be partly explained by the renal loss of magnesium due to decreased resorption as well as decreased absorption, as PPI are capable of altering the pH of the gastrointestinal tract, thereby decreasing absorption mediated by TRPM6 and TRPM7 transporters \[32\]."

8\. Did the investigator exclude kidney transplant patients?

Answer: All patients with kidney transplantation and / or on RRT were not included in this study. To make this information clearer, we added this information to the exclusion criteria:

"\[\...\] Patients who underwent previous kidney transplantation and/or patients on renal replacement therapy, and patients who had missing data related to some of the variables used during the two-year follow-up were not included in this study." (Methods section)

9\. The STROBE checklist is needed to be followed. There are a number of consistent inaccuracies in the manuscript that I strongly believe need to be addressed before the paper can be reviewed again.

Answer: As proposed by the reviewer the STROBE checklist was revised after all modifications. Below is the properly completed STROBE checklist, demonstrating that all steps to properly write this manuscript have been checked:

10\. Please discuss in the limitations the types of biases the findings of this study may be influenced by.

As described in the discussion although limitations have been identified, for each of them alternatives were worked out to minimize possible interference in the final result:

• Selection bias was minimized using the entire outpatient population (users and non-users) of CKD patients, thus preventing the selection of only omeprazole users who evolved to CKD.

• Regarding the information bias, two sources (medical records and SIS data) were used to validate all collected data. Thus, the results represent, in fact, the reality of patients with the lowest possible risk of information errors.

• Regarding drug classes: we worked with the total number of drugs in use per patient. This way of working was determined to minimize the impacts of those unregistered medications.

• Some variables with a large amount of missing data detected at the time of data collection, so that there were no results induced by the absence of data, were withdrawn from the study. Assessed the impact of each variable of being a confounding variable before withdrawal, thus being confirmed as not influencing the final outcome.

11\. Some revision of the English language is needed. There are some parts of the paper where it is quite difficult to make sense of some sentences. English edit will help to improve the quality of the manuscript.

"they identified that PPI are associated" is not correct in grammar.

RE "medicine use were collected from all patients diagnosed with CKD"; "medicine use" should be "medication use"

RE "the progressive decrease of renal function" "of" should be "in"

"In addition, considering the high consumption of PPI in the world and 78 in the Brazilian population \[14\] and their adverse effects on renal functions, perform research to contribute to the reduction of the knowledge gap with respect to this association, and of the very use of these drugs, is paramount." Is not well written and difficult to follow.

Answer: For a better clarification of the text, the sentences have been corrected as follows:

"However, recent studies found that loss of renal function is not necessarily caused by sequential acute lesions, as the use of PPI has been associated with CKD regardless of the occurrence of previous acute episodes \[8,10\].

"Information about clinical and sociodemographic data, health behaviors, and medication use was collected from all patients diagnosed with CKD through consultation of medical charts and the Brazilian health information system (SIS)."

"Chronic kidney disease (CKD), characterized by progressive deterioration of biochemical and physiological functions of the body systems, can be defined as a syndrome caused by the progressive decrease in renal function \[1-4\]."

"In addition, considering the high consumption of PPI in Brazil \[14\] and in the world population, as well their adverse effects, it is necessary to conduct researches to better elucidate this association."

In order to guarantee the application of English grammar standards, this manuscript has been reviewed by a qualified professional. Thus, minor corrections were also made throughout the text, highlighted in yellow. Attached is proof of revision:

Reviewer \#2:

Dear author,

Thanks for interesting article that brings new evidence of the renal toxicity of the proton pump inhibitor.

I would like to clarify a few points:

major revision:

The group with proton pump inhibitor has a higher blood pressure than the group without proton pump inhibitor. This difference alone can explain the progression of renal failure. It is not clear that this has been taken into account in the multivariate analysis.

Answer: In fact, blood pressure could be a factor that could explain CKD progression, since hypertension is one of the main underlying diseases, and also one of the factors that worsen prognosis when not controlled. Although a statistically significant difference was found when comparing the users and non-users of omeprazole groups by Pearson's chi-square test, when performing univariate COX analysis to identify the variables eligible for the multivariate adjustment model, this variable did not presented statistical significance (p\> 0.20), indicating that this is not a confounding variable in this study. Therefore, this variable was not included in the multivariate analysis. It is noteworthy that all variables were tested in the univariate model, and only the variables Omeprazole use (exposure) and ARBs use were statistically significant for inclusion in the multivariate model. To make this information better understood, the following text was added to the manuscript:

"The use of the other drugs evaluated (NSAIDs, ACE inhibitors, ARBs) and blood pressure presented p-value\> 0.20 in the univariate Cox analysis, showing that these are not confounding variables and, therefore, not included as adjustment variables in the multivariate analysis."

\>minor revision:

in the table on page 10, for which data with ACEs do not appear?

R: As described above, this variable was not statistically significant in the univariate COX analysis (p\> 0.20), and therefore was not included in the multivariate analysis.

\> This is not the first time a study has focused on the progression of kidney failure. For example, XIE Y JASN 2016 has demonstrated a link between proton pump inhibitor and 30% decrease in GFR or doubling of creatinine level.

R: In fact, the article discusses the evolution of CKD in patients using PPIs, so it was rescued by the authors and used to make the discussion of the use of PPIs more robust and the evolution of kidney disease. In addition, this information has been corrected in the Introduction section. Thus, the following excerpt was inserted in the discussion section:

"In recent meta-analysis, Wijarnpreecha et al. (2017) found a 1.3-fold increased risk for CKD onset and evolution to ESRD for PPI users. For the H2 antagonist users this risk was not found \[59\]. Xie et al. (2016) found in a cohort study that PPI users have a higher risk of CKD onset and evolution, as well as to progression to ESRD, when compared to users of H2 antagonists and controls \[60\]."

With kind regards,

The authors.
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